Enrollment initiated for VS-7375 in combination with cetuximab in patients with advanced KRAS G12D mutant solid tumors, including colorectal cancer Plan to report an interim safety and efficacy update ...

Phase 1 dose-escalation study to evaluate VS-7375 in the U.S., with plans to expand as monotherapy into pancreatic cancer and non-small cell lung cancer cohorts, along with colorectal cancer in ...

Verastem (VSTM) stock receives a "Buy" rating, driven by progress in KRAS G12D-targeted therapies and multiple 2026 catalysts ...

Enrollment is ongoing in U.S. Phase 1/2a trial for VS-7375, an oral KRAS G12D (ON/OFF) inhibitor, in KRAS G12D advanced solid tumors KRAS G12D mutation is the most prevalent KRAS mutation in human ...

VS-7375, an oral KRAS G12D inhibitor, received FDA clearance for clinical trials in advanced solid tumors, including pancreatic, colorectal, and non-small cell lung cancers. Verastem Oncology will ...

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced positive ...

Verastem (VSTM) “announced encouraging preliminary data from the first two dose levels in its ongoing Phase 1/2a clinical trial evaluating VS-7375, a potential best-in-class oral KRAS G12D (ON/OFF) ...

Expect to initiate a Phase 1/2a trial in the U.S. in advanced KRAS G12D mutant solid tumors in mid-2025 Initial safety and efficacy results from the trial of VS-7375 by partner GenFleet Therapeutics ...

91.5% of patients experienced a reduction in tumors and a disease control rate of 96.7%; nearly half the patients evaluated remain on treatment Low discontinuation rate due to adverse events of 4% ...

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the U.S. Food and Drug ...